Veradigm - MDRX Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veradigm in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDRX, but not buy additional shares or sell existing shares.
View MDRX analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued 1-year price objectives for Veradigm's shares. Their MDRX share price forecasts range from $17.00 to $26.00. On average, they predict the company's stock price to reach $20.90 in the next twelve months. This suggests a possible upside of 60.2% from the stock's current price.
View analysts price targets for MDRX or view top-rated stocks among Wall Street analysts.

Veradigm's stock was trading at $17.64 at the beginning of the year. Since then, MDRX stock has decreased by 26.0% and is now trading at $13.05.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our MDRX earnings forecast.

Veradigm Inc. (NASDAQ:MDRX) released its quarterly earnings results on Thursday, November, 4th. The software maker reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.09. The software maker earned $369 million during the quarter, compared to analyst estimates of $376.09 million. Veradigm had a net margin of 7.25% and a trailing twelve-month return on equity of 10.74%. Veradigm's quarterly revenue was down 8.2% on a year-over-year basis. During the same period last year, the company earned $0.15 earnings per share.

ETFs with the largest weight of Veradigm (NASDAQ:MDRX) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Invesco Dynamic Software ETF (PSJ), Harbor Health Care ETF (MEDI), Invesco S&P SmallCap Health Care ETF (PSCH), Fidelity Digital Health ETF (FDHT), Invesco DWA Healthcare Momentum ETF (PTH), Inspire Fidelis Multi Factor ETF (FDLS) and Cambria Shareholder Yield ETF (SYLD).

Veradigm declared that its Board of Directors has authorized a stock repurchase program on Wednesday, May 26th 2021, which authorizes the company to repurchase $350,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 14% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board believes its shares are undervalued.

Veradigm issued an update on its FY 2023 earnings guidance on Wednesday, March, 22nd. The company provided earnings per share (EPS) guidance of $0.80-$0.90 for the period, compared to the consensus EPS estimate of $0.90. The company issued revenue guidance of $615.00 million-$635.00 million, compared to the consensus revenue estimate of $649.05 million.

796 employees have rated Veradigm Chief Executive Officer Paul Black on Glassdoor.com. Paul Black has an approval rating of 65% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veradigm investors own include Advanced Micro Devices (AMD), Netflix (NFLX), Energy Transfer (ET), CVS Health (CVS), Ford Motor (F), Himax Technologies (HIMX), Intel (INTC), OPKO Health (OPK), Tesla (TSLA) and Activision Blizzard (ATVI).

Veradigm trades on the NASDAQ under the ticker symbol "MDRX."

Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDRX stock can currently be purchased for approximately $13.05.

Veradigm (NASDAQ:MDRX) has a market capitalization of $1.43 billion and generates $1.50 billion in revenue each year. The software maker earns $134.44 million in net income (profit) each year or $0.43 on an earnings per share basis.

The company employs 8,000 workers across the globe.

Veradigm's mailing address is 222 MERCHANDISE MART PLAZA SUITE 2024, CHICAGO IL, 60654. The official website for the company is www.allscripts.com. The software maker can be reached via phone at (800) 334-8534, via email at stephen.shulstein@allscripts.com, or via fax at 313-322-9600.